BTC Health Ltd (BTC) fair value: what the stock is really worth
As of Nov 2, 2026: fair value (intrinsic value) of BTC Health Ltd stock A$0.03, price A$0.05, that is 38.8% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range A$0.0150 – A$0.0880 · the A$0.0480 price screens above the A$0.0294 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow BTC Health in your weekly email
Every Wednesday you see whether BTC Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments.
Show moreShow less
It makes investments in the healthcare, acute pain management, neuro-spinal, cardiovascular, pharmaceutical, medical technologies, biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine.
Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies.
Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox.
It invests in companies based in Australia & New Zealand. The fund invests in both listed and unlisted companies.
Stock analysis
BTC Health Ltd (BTC) currently trades at A$0.0480, while our model-based Fair Value estimate is A$0.0294, 39% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of A$0.0300 per share, and 1 of the 4 models we run sit above the A$0.0480 price.
Bear case: the Economic Profit group reads lowest at A$0.0200, and 3 of the 4 models stay below the price. Data coverage for this calculation is low.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BTC Health Ltd reported revenue of A$29.4K in FY2026 versus A$95.0K in FY2022, a compound −25.4%/yr. Reported net income was A$34.7K in FY2026.
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −39%, BTC screens richer than that median.
Fair Value models
BearA$0.0294Fair Value A$0.0294BullA$0.0294
Price A$0.0480 · Downside -38.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual IncomeA$0.0200A$0.0200A$0.020066
EV/EBITA$0.0100A$0.0100A$0.010063
EV/EBITDAA$0.0200A$0.0300A$0.040063
All 6 models by family
Earnings-Based
Graham-Doddn/an/aA$0.010059
Multiples
P/B MultipleA$0.0500A$0.0700A$0.080055
EV/EBITA$0.0100A$0.0100A$0.010063
EV/EBITDAA$0.0200A$0.0300A$0.040063
Economic Profit
Residual IncomeA$0.0200A$0.0200A$0.020066
Growth Earnings
Growth-Adj P/En/an/aA$0.010060
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−69.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−69.2%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1,717% → 118%
⚠ Revenue per share shrinking 13.0%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 6/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score37 · Below median
Fair Value upside−38.8% · Above median
Profitability
Return on equity (12 months)0.3% · Above median
Return on assets0.3% · Above median
Net margin (12 months)118.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)10.7% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.53× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)54· sector 0
PAST (return on equity)1· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BTC Health Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BTC
Frequently asked questions
Is BTC Health Ltd (BTC) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.0294 versus the last price from Nov 2, 2026 of A$0.0480, about 39% lower (overvalued).
What is the fair value of BTC?
Our model-based fair value for BTC Health Ltd is A$0.0294 (as of Nov 4, 2026), built from audited fundamentals. Last price (from Nov 2, 2026): A$0.0480.
What is the quality score of BTC?
BTC Health Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BTC Health Ltd (BTC)?
Our model-based price target is the fair value of A$0.0294 (as of Nov 4, 2026) from 6 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the BTC Health Ltd stock forecast for 2026?
Our models put fair value at A$0.0294, about 39% lower versus the last price from Nov 2, 2026 of A$0.0480 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of BTC Health Ltd (BTC)?
BTC Health Ltd reported trailing-twelve-month revenue of about A$29.4K (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of BTC Health Ltd (BTC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BTC Health Ltd it is A$0.0294 per share (as of Nov 4, 2026), against a price of A$0.0480. It is the blended result of 6 valuation models in 4 families (Earnings-Based, Multiples, Economic Profit, Growth Earnings).
Is BTC Health Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, BTC trades above its calculated fair value: price A$0.0480, fair value A$0.0294, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BTC?
No. The price is what the market pays today (A$0.0480); the fair value is what the company's own numbers justify (A$0.0294). For BTC Health Ltd the two are A$0.0186 per share apart. That gap is exactly why we show both numbers side by side.
How much is BTC Health Ltd worth?
The market values BTC Health Ltd at about A$17.2M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.0480; our models calculate a fair value of A$0.0294 per share.
How solid is the balance sheet of BTC Health Ltd (BTC)?
Balance-sheet figures for BTC Health Ltd (as of Nov 4, 2026): return on equity 0.3%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is BTC from its 52-week high?
BTC Health Ltd trades at A$0.0480, about 31% below its 52-week high of A$0.0700 and at the low of A$0.0480 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0294 is for.
Which stocks are comparable to BTC Health Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BTC Health Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.0480, calculated fair value A$0.0294 (−39%), Quality Score 37/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BTC calculated?
We run BTC Health Ltd through 6 models from 4 families: Earnings-Based, Multiples, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$0.0294 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BTC Health Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BTC Health Ltd (BTC)?
The latest price we hold is from Nov 2, 2026 and stands at A$0.0480. Our model-based fair value is A$0.0294, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BTC Health Ltd right now?
The price sits above even our optimistic bull case (A$0.0294). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of BTC Health Ltd
How large is the market capitalisation of BTC Health Ltd (BTC)?
The market capitalisation of BTC Health Ltd is A$17.2M (≈ $11.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of BTC Health Ltd (BTC)?
The net margin of BTC Health Ltd is 118% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BTC Health Ltd (BTC)?
The return on equity (ROE) of BTC Health Ltd is 0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BTC Health Ltd (BTC)?
On an EBIT basis the return on assets of BTC Health Ltd is −7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BTC Health Ltd (BTC)?
The operating margin of BTC Health Ltd is −566% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BTC Health Ltd (BTC)?
Revenue at BTC Health Ltd is growing +10.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BTC Health Ltd (BTC)?
Earnings per share at BTC Health Ltd are growing +176% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BTC Health Ltd (BTC) generate?
The free cash flow of BTC Health Ltd is −A$354K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BTC Health Ltd (BTC) hold?
BTC Health Ltd holds more cash than debt, A$1.5M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch BTC Health Ltd in the live analysis
One click puts BTC Health Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026
